use of ivabradine leads to a total cost saving of €4826 per patient over 5 years. The use of ivabradine also leads to a higher effectiveness, as it reduces the average number of revascularisation procedures from 1.100 to 0.143, including the initial revascularisation procedures for the standard care arm of the model. The number of revascularisations during the 5-year period is about similar, when excluding the initial revascularisation procedure (0.100 to 0.143). Sensitivity analyses show that ivabradine remains cost saving over the complete range of the input variables. CONCLUSIONS: Ivabradine is a cost-effective treatment and, in fact, a dominant treatment: Ivabradine yields to a higher effectiveness as standard treatment with respect to number of revascularisations, but leads to substantial overall cost savings. OBJECTIVES: To estimate the cost-effectiveness of atorvastatin 10 mg compared with no treatment for the primary prevention of cardiovascular (CV) events in Type 2 diabetes patients with no CV history. METHODS: A Markov model with 1-year cycles was developed to simulate the CV event and death risk according to the therapeutic approach initiated. The transition probabilities for CV event in the 'no statin treatment' group were derived from the risk-equations reported from the large UK Prospective Diabetes Study (UKPDS). The hazard ratio (HR) from the CARDS clinical trial (0.63; 95% confidence interval [CI], 0.48, 0.83; P = 0.001) was used to adjust these CV event probabilities in the atorvastatin 10 mg treatment group. Characteristics of Type 2 diabetes patients with no CV history were derived from the Belgian Optimize Cardiovascular Prevention in Diabetes (OCAPI) survey. The public health care payers' perspective was taken into account for costing. The direct medical costs of CV events were based on the Public Health Authorities' hospital database for acute care costs and on literature for follow up costs. Drug cost did consider the impact of generic entry on the reimbursement system. Costs were valued at year 2008; costs and outcomes were respectively discounted at 3 and 1.5%. RESULTS: Based on a 5-year time horizon, atorvastatin was demonstrated to be cost-effective with an incremental cost/QALY of €23,426. Over a lifetime horizon (25 years), atorvastatin was a cost-neutral therapeutic approach (€9/ QALY). At a threshold of €30,000/QALY, atorvastatin had a 99.3% probability to be cost-effective. Furthermore, for higher risk diabetic patients managed in specialist hospital diabetes centres, atorvastatin was cost-saving. CONCLUSIONS: Compared to no treatment, the use of atorvastatin 10 mg as a primary prevention strategy in Type 2 diabetes patients not only appears to be cost-neutral over a lifetime, but improves CV outcomes. OBJECTIVES: Following broadening of the EMEA license for advanced follicular lymphoma (FL) which now allows first line treatment with rituximab added to chemotherapy without restriction to the regimen, we evaluated the cost-effectiveness of rituximab added to commonly used chemotherapy regimens from the perspective of the UK national health care system. METHODS: A Markov model was developed using published results from 4 phase III randomized-controlled clinical trials evaluating progression-free survival (PFS) and overall survival (OS) in patients with advanced FL. These trials compared the addition of rituximab to chemotherapy regimens of either MCP, CVP, CHOP or CHVP versus chemotherapy alone. Rates of disease progression were derived from the PFS Kaplan-Meier curves using parametric curve fitting, mortality rates were obtained from the Scotland-Newcastle Lymphoma Group database and UK age-specific mortality tables. FL patient utilities elicited using the EQ-5D were applied to PFS and progressed health states. The duration of the treatment effect of rituximab was applied for the period of follow-up specified in each of the clinical trial publications. Medication, supportive care costs and quality-adjusted life years (QALYs) were estimated over a lifetime time horizon (25 years) and discounted at 3.5% per annum. Univariate and probabilistic sensitivity analysis was performed to evaluate uncertainty. RESULTS: The addition of rituximab to chemotherapy increased QALYs by 1.223, 1.034, 0.858 and 0.471 years for MCP, CVP, CHOP and CHVP, respectively, compared to chemotherapy alone. The incremental cost per QALY gained was £5620, £6455, £7970 and £8422, for MCP, CHOP, CVP and CHVP, respectively, all below commonly used thresholds in the UK. Sensitivity analyses indicated these results were robust, and most sensitive to the duration of treatment effect. CONCLUSIONS: For all chemotherapy regimens evaluated, the model demonstrated the addition of rituximab increased qualityadjusted life expectancy and is a highly cost-effective treatment option for patients with advanced FL. OBJECTIVES: The impact of cervical cancer prevention, through 12-year-old female vaccination with Cervarix TM (Glaxo-SmithKline), has been published for many countries at the national level. However, to our knowledge no attempt has been made to address the impact at a regional level. Since the Italian health reforms of the early 1990s, introducing "managerialism", decentralization and quasi-market mechanisms; regional authorities have consequently been experimenting with different organizational and funding models to achieve an acceptable combination of equity, efficiency, freedom of choice and costcontainment. METHODS: A Markov model, previously described and successfully adapted to the national scenario (La Torre, 2007), has been used to explore the impact of prophylactic cervical cancer vaccination with Cervarix TM at a regional level in Italy. Resource use was based on a standard therapeutic path applied to all regions. However we quantified the impact of the so-called "decentralization progress" by collecting regional data on: Pap-test coverage, tariffs for treatments and cost of the vaccination course. The analyses were combined with regional budget impact analyses, considering the demography and the effective tender price for each region. RESULTS: Our analyses demonstrated the heterogeneity present at regional level in Italy (e.g. regular screening, ranges from 36% to 84%; cost of cervical Abstracts A343
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PODIUM SESSION II: ECONOMIC EVALUATIONS II EE5 COST-EFFECTIVENESS OF ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: A PHARMACO-ECONOMIC ANALYSIS OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS) IN THE BELGIAN POPULATION
Marbaix S 1 ,Vandenberghe H 1 ,Van Gaal L 2 1 Pfizer WPO Belgium, Brussels, Belgium, 2 Antwerp University Hospital, Edegem, Belgium OBJECTIVES: To estimate the cost-effectiveness of atorvastatin 10 mg compared with no treatment for the primary prevention of cardiovascular (CV) events in Type 2 diabetes patients with no CV history. METHODS: A Markov model with 1-year cycles was developed to simulate the CV event and death risk according to the therapeutic approach initiated. The transition probabilities for CV event in the 'no statin treatment' group were derived from the risk-equations reported from the large UK Prospective Diabetes Study (UKPDS). The hazard ratio (HR) from the CARDS clinical trial (0.63; 95% confidence interval [CI], 0.48, 0.83; P = 0.001) was used to adjust these CV event probabilities in the atorvastatin 10 mg treatment group. Characteristics of Type 2 diabetes patients with no CV history were derived from the Belgian Optimize Cardiovascular Prevention in Diabetes (OCAPI) survey. The public health care payers' perspective was taken into account for costing. The direct medical costs of CV events were based on the Public Health Authorities' hospital database for acute care costs and on literature for follow up costs. Drug cost did consider the impact of generic entry on the reimbursement system. Costs were valued at year 2008; costs and outcomes were respectively discounted at 3 and 1.5%. RESULTS: Based on a 5-year time horizon, atorvastatin was demonstrated to be cost-effective with an incremental cost/QALY of €23,426. Over a lifetime horizon (25 years), atorvastatin was a cost-neutral therapeutic approach (€9/ QALY). At a threshold of €30,000/QALY, atorvastatin had a 99.3% probability to be cost-effective. Furthermore, for higher risk diabetic patients managed in specialist hospital diabetes centres, atorvastatin was cost-saving. CONCLUSIONS: Compared to no treatment, the use of atorvastatin 10 mg as a primary prevention strategy in Type 2 diabetes patients not only appears to be cost-neutral over a lifetime, but improves CV outcomes.
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COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
Ray JA 1 , Carr E 1 , Geary U 2 1 F. Hoffmann-La Roche, Basel, Switzerland, 2 Roche Products Limited, Hertfordshire, UK OBJECTIVES: Following broadening of the EMEA license for advanced follicular lymphoma (FL) which now allows first line treatment with rituximab added to chemotherapy without restriction to the regimen, we evaluated the cost-effectiveness of rituximab added to commonly used chemotherapy regimens from the perspective of the UK national health care system. METHODS: A Markov model was developed using published results from 4 phase III randomized-controlled clinical trials evaluating progression-free survival (PFS) and overall survival (OS) in patients with advanced FL. These trials compared the addition of rituximab to chemotherapy regimens of either MCP, CVP, CHOP or CHVP versus chemotherapy alone. Rates of disease progression were derived from the PFS Kaplan-Meier curves using parametric curve fitting, mortality rates were obtained from the Scotland-Newcastle Lymphoma Group database and UK age-specific mortality tables. FL patient utilities elicited using the EQ-5D were applied to PFS and progressed health states. The duration of the treatment effect of rituximab was applied for the period of follow-up specified in each of the clinical trial publications. Medication, supportive care costs and quality-adjusted life years (QALYs) were estimated over a lifetime time horizon (25 years) and discounted at 3.5% per annum. Univariate and probabilistic sensitivity analysis was performed to evaluate uncertainty. RESULTS: The addition of rituximab to chemotherapy increased QALYs by 1.223, 1.034, 0.858 and 0.471 years for MCP, CVP, CHOP and CHVP, respectively, compared to chemotherapy alone. The incremental cost per QALY gained was £5620, £6455, £7970 and £8422, for MCP, CHOP, CVP and CHVP, respectively, all below commonly used thresholds in the UK. Sensitivity analyses indicated these results were robust, and most sensitive to the duration of treatment effect. CONCLUSIONS: For all chemotherapy regimens evaluated, the model demonstrated the addition of rituximab increased qualityadjusted life expectancy and is a highly cost-effective treatment option for patients with advanced FL.
EE7 ECONOMIC ANALYSIS OF PROPHYLACTIC CERVICAL CANCER VACCINATION IN ITALY:THE NATIONAL AND REGIONAL LEVEL
Cavallo M 1 , Cipriani F 2 , Demarteau N 3 , Gerzeli S 1 , Marocco A 2 , Bamfi F 2 1 Bocconi University, Milano, Italy, 2 GlaxoSmithKline Spa, Verona, Italy, 3 GlaxoSmithKline Biologicals, Wavre, Belgium OBJECTIVES: The impact of cervical cancer prevention, through 12-year-old female vaccination with Cervarix TM (Glaxo-SmithKline), has been published for many countries at the national level. However, to our knowledge no attempt has been made to address the impact at a regional level. Since the Italian health reforms of the early 1990s, introducing "managerialism", decentralization and quasi-market mechanisms; regional authorities have consequently been experimenting with different organizational and funding models to achieve an acceptable combination of equity, efficiency, freedom of choice and costcontainment. METHODS: A Markov model, previously described and successfully adapted to the national scenario (La Torre, 2007) , has been used to explore the impact of prophylactic cervical cancer vaccination with Cervarix TM at a regional level in Italy. Resource use was based on a standard therapeutic path applied to all regions. However we quantified the impact of the so-called "decentralization progress" by collecting regional data on: Pap-test coverage, tariffs for treatments and cost of the vaccination course. The analyses were combined with regional budget impact analyses, considering the demography and the effective tender price for each region. RESULTS: Our analyses demonstrated the heterogeneity present at regional level in Italy (e.g. regular screening, ranges from 36% to 84%; cost of cervical Abstracts A343 cancer treatment ranges from €10,251 to €13,934). The national ICER was €26,361 per QALY, but the net cost per subject vaccinated differed across regions impacting the affordability to vaccinate multiple cohorts 12-years/catch-up to 16-years. CON-CLUSIONS: National analyses, using national 'average' data, are the necessary starting point for the evaluation of new health technologies, addressing centralized regulatory agency requirements. However, in the Italian scenario, characterized by decentralization and local autonomy, a further level of detail is essential in order to describe the regional impact to budget holders thereby better informing local decision makers and facilitating the uptake of cost-effective health care interventions.
EE8 COST EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX) COMPARED TO FOLFOX (5-FU, LV, OXALIPLATIN) FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUM (CRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
Millar DR 1 , Ducournau P 2 , McDonald A 3 1 Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK, 2 F. Hoffmann-La Roche, Basel, Switzerland, 3 Western Infirmary, Glasgow, UK OBJECTIVES: Capecitabine's mCRC licence was recently extended supporting its use in combination therapy. This study evaluated the cost effectiveness of replacing FOLFOX, with XELOX. METHODS: Based on results from phase 3 trials, demonstrating that XELOX is non-inferior to FOLFOX4 (NO16966 1 st line; NO16967 2 nd line), a cost minimisation analysis was performed evaluating incremental costs from the start of treatment until disease progression. Dose, treatment duration, adverse event frequency and the probability of central venous access device (CVAD) replacement were taken directly from the NO16966/7 trials. Drug costs were based on the UK list price. Administration, pharmacy and adverse event costs were taken from NHS reference costs 2005/6, the literature, and previous technology appraisals. Clinical practice assumptions were: 10% and 100% of XELOX and FOLFOX patients receive a CVAD respectively; 25% of 5FU infusions require an overnight stay in hospital, the remaining 75% use an ambulatory pump at home; 30% of patients receive hospital funded transport. Uncertainty was explored via one-way sensitivity analysis and a scenario of FOLFOX6 being replaced in 1 st line (ceteris paribus) was also evaluated. RESULTS: Per patient, replacing FOLFOX4 with XELOX, saved (1 st /2 nd line) £578/£498 drug acquisition, £773/ £341 CVAD placement, £8078/£5561 pharmacy and administration, and £173/£17 adverse event costs. Total savings were £9611 and £6405 1 st and 2 nd line respectively. In all of the scenarios evaluated in the sensitivity analysis XELOX was cost saving by more than £8636 per patient 1 st line, and £5702 2nd line, compared to FOLFOX4. XELOX remained cost saving (~£6500) when compared to FOLFOX6. CONCLUSIONS: Replacing FOLFOX with XELOX offers the NHS considerable savings in terms of administration and pharmacy, and to a lesser extent drug acquisition costs, with equivalent efficacy. Additionally patients may prefer XELOX due to the reduction in hospital administration visits and probability of requiring a CVAD.
PODIUM SESSION II: MENTAL HEALTH II (SCHIZOPHRENIA IN EUROPE) MH5 EFFECT OF A NURSE TELEPHONE FOLLOW-UP ON THERAPEUTIC ADHERENCE OF PATIENTS WITH SCHIZOPHRENIA
Maurino J 1 , Montes JM 2 , Saiz Ruiz J 3 , Claret J 4 , Diez T 1 1 AstraZeneca, Madrid, Spain, 2 Hospital del Sureste, Arganda del Rey, Spain, 3 Hospital Ramon y Cajal, Madrid, Spain, 4 Fundació Hospital de Día Nou Barris, Barcelona, Spain OBJECTIVES: To evaluate the effect of a nurse telephone follow-up as a strategy for improving therapeutic adherence among outpatients with schizophrenia. METHODS: A 16-week, open, multicentre, randomised controlled trial. Patients fulfilled criteria for schizophrenia (DSM-IV TR criteria). To be eligible, patients had to be ambulatory in treatment with an oral antipsychotic agent. Participants were randomised to receive monthly telephone calls from a nurse of mental health center or standard clinical follow-up. Phone calls were performed at weeks 4, 8, and 12 in the intervention arm. The calls consisted of a brief interview to assess treatment compliance and Drug Attitude Inventory (DAI-10). A compliance with Ն60% of doses was used to classify patients as compliant. Primary endpoint was the difference in the percentage of compliant patients after nurse telephone follow-up versus control group at week 16. Secondary endpoints included socio-demographic data, past mental health diagnosis, Clinical Global Impression-Schizophrenia (CGI-SCH), DAI-10, and Euroqol EQ-5D. Study protocol was approved by a local Ethical Committee and all patients provided written informed consent. RESULTS: A total of 865 patients were studied, 65% men. Mean age: 40.08 years (SD = 11.6). Baseline socio-demographic and main clinical characteristics were similar between both groups: mean time from diagnosis: 13.08 years (SD = 9.5), mean number of hospitalisations in the last 5 years: 2.23 (SD = 2.7), mean time from last relapse: 3.1 years (SD = 3.9). A total of 88.2% (374) patients in the intervention arm were compliant vs 90.0% (397) in control arm. At baseline, mean CGI-SCH, DAI-10, and EQ-5D scores were similar in both groups. At week 16, 410 (96.7%) patients fulfilled compliance criteria in the intervention group vs 402 (91.1%) in the control group. An absolute difference of 5.5% was found between groups (CI95%, 2.3-8.6%; p = 0.0007); OR 3.57 (CI95%, 1.81-7.04). Mean global CGI-SCH and DAI-10 scores were better in the intervention arm: 3.07 vs 3.25 p = 0.009; 6.05 vs 5.19 p < 0.0001, respectively. CON-CLUSIONS: Despite a high baseline rate of compliance of the studied population, nurse telephone intervention increased antipsychotic adherence. A nurse telephone follow-up could be a complementary strategy to improve therapeutic adherence in schizophrenic patients.
